Non-Eosinophilic Neutrophilic Asthma

Non-Eosinophilic Neutrophilic Asthma


Hospital de la Santa Creu i Sant Pau (HSP)

Dra. Astrid Crespo Lessmann

Hospital de la Santa Creu i Sant Pau

Dra. Ana Lapuente Torrents

Hospital Mutua de Terrassa

Dr. Eder Mateus Medina

Institut de Recerca IIB Sant Pau. Barcelona

Dra. Elena Curto Sánchez

Hospital de la Santa Creu i Sant Pau. Barcelona

Dr. Jordi Giner Donaire

Hospital de la Santa Creu I Sant Pau. Barcelona

Dr. David Ramos Barbón

Hospital de la Santa Creu I Sant Pau. Barcelona

Dra. Silvia Vidal Alcorisa

Institut de Recerca IIB Sant Pau. Barcelona

Dr. Xavier Muñoz Gall

Hospital Universitari Vall d’Hebron. Barcelona

Dra. Mariana Mercedes Muñoz

Hospital Universitari de Bellvitge. L’Hospitalet de Llobregat

Dr. Carles Sabadell Nieto

Hospital de Figueres/ Fundació Salut Empordà. Figueres

Dra. Concepción Cañete Ramos

Hospital General de l’Hospitalet/Consorci Sanitari Integral. L’Hospitalet de Llobregat

Dra. Benedicta Abeijon Insua

Hospital de Terrassa/Consorci Sanitari de Terrassa

Dra. Pilar Ausin Herrero

Hospital del Mar/Consorci Parc de Salut Mar. Barcelona

Dr. Joan Serra Batlles

Hospital Universitari de Vic/Consorci Hospitalari de Vic

Dra. Ebymar Arismendi

Hospital Clínic de Barcelona

Dr. Cesar Picado Vallés

Hospital Clínic de Barcelona

Dra. Rosa Mª del Campo Moreno

Instituto Ramón y Cajal de Investigación Sanitaria. Madrid

Dr. Gustavo Rodrigo

Hospital Central de las Fuerzas Armadas de Montevideo (Uruguay)

Neutrophilic asthma (NA) is the least known phenotype of asthma, causes severe illness and has no specific treatment. Research on neutrophilic mechanisms, new types of neutrophils (NEU) and bronchial microbioma can offer an opportunity for a better understanding of their pathogenesis.

OBJECTIVES: 1. To describe the clinical characteristics of the NA and its subtypes (substudy 1); 2. To characterize the NEUs associated with it and its subtypes (substudy 2); and 3. To identify its bronchial microbial flora, in particular its association with the immune response to Chlamydia Pneumoniae (substudy 3).

METHODS: prospective multicentric study involving 100 patients with severe asthma (GEMA/GINA criteria): 50 with non-neutrophilic asthma (<65% NEU in induced sputum (IS) and 50 with NA (>64% NEU in IS).

Substudy 1: clinical variables will be collected (evolution years, exacerbations, ACT, miniAQLQ), comorbidities (RGE, nasal polyposis, obesity, SAHS), pulmonary function (FEV1, FENO, TLC, VR, KCO), blood analysis (leukocyte formula, IgE, IgG Aspergillus), prick-test and thorax CT.

Substudy 2 (in IS and plasma): apoptotic index by culture of NEU and flow cytometry (Annexin-V-FITC), NEU phenotype by surface markers (CD177, CD16, CD66b, CD62L, CD11b, CD63, HLA-DR, CXCR2, CXCR4) with density gradient study and cytokine determination (IL-6 IL-8, IL-1, IL-22, IL-17) by ELISA.

Substudy 3: (in IS and plasma): bronchial microbioma by 16S rRNa PICRUSt and anti-Chlamydia Pneumoniae IgA by ELISA.

Choose your language